Wells Fargo Initiates Coverage On Lion Biotechnologies Inc(LBIO). The shares have been rated Outperform. The rating by the stock financial advisor at Wells Fargo was issued on Mar 17, 2017 in a research report to their Investors and Clients.
Lion Biotechnologies Inc (LBIO) shares turned negative on Wednesdays trading session with the shares closing down -0.1 points or -1.38% at a volume of 2,54,447. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.4. The peak price level was also seen at $7.4 while the days lowest was $7.05. Finally the shares closed at $7.15. The 52-week high of the shares is $9.58 while the 52-week low is $4.24. According to the latest information available, the market cap of the company is $446 M.
Lion Biotechnologies Inc(LBIO) last announced its earnings results on Mar 7, 2017 for Fiscal Year 2016 and Q4.Earnings per share were $-0.2. Analysts had estimated an EPS of $-0.25.
Several Insider Transactions has been reported to the SEC. On Aug 24, 2016, Sanford Hillsberg (director) sold 54,000 shares at $9.11 per share price.
Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.